Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sodium thiosulfate formulation DB-020

An injectable sterile viscous solution composed of the thiol-containing reducing agent sodium thiosulfate (STS) pentahydrate formulated in sodium hyaluronate in sterile water that can be used to prevent ototoxicity. Upon administration into the ear via trans tympanic injection, thiosulfate targets and irreversibly binds to cisplatin. This inactivates cisplatin locally in the cochlea and prevents hearing loss caused by cisplatin without interfering with cisplatin’s anti-cancer activity. As DB-020 can be administered directly to the ear prior to each cycle of chemotherapy, it may protect the ear from cisplatin’s ototoxic effects.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:STS formulation DB-020
Code name:DB 020
DB-020
DB020
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search